**SUPPLEMENTARY TABLE**

**Workshop Delegate List**

|  |  |  |
| --- | --- | --- |
| **Name** | **Job Title** | **Institution** |
| Zoe Armstrong | Executive Director Clinical Research – Australia/New Zealand and East Asia | MSD |
| Dr Helen Bell | Research Assistant | University of Sheffield |
| Iain Bennett | Health Economic Statistician | F Hoffmann-La Roche AG |
| Andrew Bruce | Director, Health Policy and Reimbursement | AMGEN |
| Tom Burke PhD | Executive Director, Global Health Outcomes, Oncology | MSD |
| Deborah Collyar | President | Patient Advocates In Research (PAIR) |
| Dr Michael Coory | Director, Clinical Evaluation Unit 5 | Therapeutic Goods Administration |
| Dane J Dickson, MD | Director of Clinical Science | MolDX, Palmetto GBA (a CMS Administrative Contractor) |
| Emeritus Professor Anthony Fields | Chair, pCODR Expert Review Committee | Canadian Agency for Drugs & Technologies in Health (CADTH) |
| Professor Davina Ghersi | Senior Principal Research Scientist | National Health and Medical Research Council (NHMRC) |
| Mendel Grobler | Director: Strategic Access and Policy | Pfizer |
| Dr Katarina Hedman, PhD Med, MSc/BSc Math, EMBA | Head, Statistical Innovation | Advanced Analytics Centre, AstraZeneca |
| Dr Phil Haywood | Health Economist | Centre for Health Economics Research and Evaluation (CHERE) |
| Dr Chris Henshall | Consultant |  |
| Dr Suzanne Hill | PBAC Chair | Pharmaceutical Benefits Advisory Committee (PBAC) |
| Professor Michael James | Chief Medical Scientist, Rheumatology Unit, Royal Adelaide Hospital | Bellberry Limited |
| Dr Daniel Kalanovic, MD | Medical Director Oncology | Pfizer |
| Dr Nick Latimer | Senior Research Fellow in Health Economics | University of Sheffield |
| Dr Wendy Lipworth | Senior Research Fellow | University of Sydney |
| Dr Jennie Louise | Medical Ethicist / Statistician | University of Adelaide |
| Clare McGrath | Oncology TA Head, Global Payer Evidence , Pricing and HTA Policy | Global Medicines Development, AstraZeneca |
| Andrew Mitchell | Strategic Adviser, Evaluation | Australian Government Department of Health |
| Dr Francesco Pignatti | Head of Oncology, Haematology and Diagnostics | European Medicines Agency (EMA) |
| Adriana Platona | Assistant Secretary, Pharmaceutical Evaluations Branch, Department of Health | Australian Government Department of Health |
| Dr Klaus Pugner | Executive Director, Global Health Economics | AMGEN |
| James Reimann | Global Head, Oncology Biostatistics and PCOR | Roche/Genentech |
| Professor Andrew Roberts | Metcalf Chair of Leukaemia Research | University of Melbourne, WEHI & Melbourne Health |
| Emeritus Professor Lloyd Sansom AO | Bellberry Board of Directors, Special Advisor Department of Health & Ageing | Bellberry Limited |
| Dr Prudence Scott | Co-Director, Oncology/ Haematology Evaluation Unit | Therapeutic Goods Administration |
| Dr Nick Simpson | Director, Clinical Evaluation Unit 4 | Therapeutic Goods Administration |
| Mike Smith | Head, Health Economics | Astrazeneca Australia |
| Dr Katherine Soltys MD | Manager, Oncology Division 1, Therapeutic Products Directorate, Health Canada | Therapeutic Products Directorate, Health Products and Food Branch, Health Canada |
| Tim Spelman | Biostatistician | Burnet Institute |
| Mike Spencer | International Brand Value Team Leader, Ibrutinib | Janssen-Cilag |
| Kylie Sproston | Chief Executive Officer | Bellberry Limited |
| Rebecca Trowman Day | Consultant Technical Adviser | National Institute for Health & Care Excellence (NICE) |
| Sean Tunis, MD,  | President and Chief Executive Officer | Center for Medical Technology Policy (USA) |
| Janet Wale | Health Technology Assessment International (HTAI) Patients & Citizens Chair | Cochrane Collaboration |
| Professor Robyn Ward AM | Professor of Medicine and Clinical Associate Dean | University of NSW and Prince of Wales Hospital |
| Dr Beate Wieseler | Head of Drug Assessment | Institute for Quality & Efficiency in Health Care (IQWiG) |
| Professor Dr Bernhard Wörmann | Medical Director | DGHO German Society for Hematology and Medical Oncology |

**Scientific Committee Membership**

|  |  |  |
| --- | --- | --- |
| **Name** | **Job Title** | **Institution** |
| Professor Keith Abrams | Professor of Medical Statistics and    Head of Unit, Studies of Health Populations and Society | University of Leicester |
| Meindert Boysen | Programme Director - Technology Appraisals | National Institute for Health and Care Excellence (NICE) |
| Mendel Grobler | Director: Strategic Access and Policy | Pfizer |
| Clare McGrath | Oncology TA Head, Global Payer Evidence, Pricing and HTA Policy | AstraZeneca |
| Francesco Pignatti | Head of Oncology, Haematology and Diagnostics | European Medicines Agency |
| James Reimann | Global Head, Oncology Biostatistics and PCOR | Roche/Genentech |
| Professor Lloyd Sansom AO | Emeritus Professor  | University of South Australia |
| Professor Uwe Siebert | Adjunct Professor of Health Policy and Management | Harvard University |
| Tim Spelman | Biostatistician | Burnet Institute |
| Mona Sabharwal | Executive Director | pan-Canadian Oncology Drug Review (pCODR), CADTH |
| Rajeshwari Sridhara | Director, Division of Biometrics V | Food and Drug Administration |
| Rebecca Trowman Day | Consultant Technical Adviser | National Institute for Health & Care Excellence (NICE) |
| Sean Tunis, MD,  | President and Chief Executive Officer | Center for Medical Technology Policy (USA) |
| Professor Bernhard Wörman | Medical Director | DGHO German Society for Hematology and Medical Oncology |
| In attendance: |
| Scientific Secretariat |
| Nick Latimer | Senior Research Fellow in Health Economics | University of Sheffield |
| Helen Bell | Research Assistant | University of Sheffield |
| Others: |
| Chris Henshall | Associate Professor | Brunel University London |
| Kylie Sproston | Chief Executive Officer | Bellberry Limited |